Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

A new chance for SCID gene therapy

Nature Medicine volume 4, pages 19–20 (1998)Cite this article

Constitutive expression of a Jak-3 transgene reverses severe combined immunodeficiency in a mouse model (pages 58–64).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Anderson, W.F. Prospects for human gene therapy. Science 226, 401–409 (1984).

    CAS  Google Scholar 

  2. Blaese, R.M. et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475–480 (1995).

    Article  CAS  Google Scholar 

  3. Hoogerbrugge, P.M. et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179–183 (1996).

    CAS  PubMed  Google Scholar 

  4. Bordignon, C. et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science 270, 470–475 (1995).

    Article  CAS  Google Scholar 

  5. Kohn, D.B. et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med. 1, 1017–1023 (1995).

    Article  CAS  Google Scholar 

  6. Bunting, K.D., Sangster, M.Y., Ihle, J.N. & Sorrentino, B.P. Restoration of lymphocyte function in Janus Kinase 3-deficient mice by retroviral-mediated gene transfer. Nature Med. 4, 58–64 (1998).

    Article  CAS  Google Scholar 

  7. Macchi, P. et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65–68 (1995).

    Article  CAS  Google Scholar 

  8. Candotti, F. et al. In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J. Exp. Med. 183, 2687–2692 (1996).

    Article  CAS  Google Scholar 

  9. Thomis, D.C. & Berg, L. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J. Exp. Med. 185,197–206 (1997).

    Article  CAS  Google Scholar 

  10. Ferrari, G. et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251,1363–1366 (1991).

    Article  CAS  Google Scholar 

  11. Candotti, F. et al. A structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 10, 3995–4003 (1997).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Scientifico H.S. Raffaele, 20132, Milan, Italy

    Claudio Bordignon

Authors
  1. Claudio Bordignon
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bordignon, C. A new chance for SCID gene therapy. Nat Med 4, 19–20 (1998). https://doi.org/10.1038/nm0198-019

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nm0198-019

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing